Abfero Pharmaceuticals is developing oral iron chelators, specifically the small molecule SP-420, to treat systemic and local iron overload disorders that can lead to severe organ damage and neurodegenerative diseases. Their technology targets iron accumulation in the body, providing a safer and more tolerable treatment option for patients at risk due to transfusions or genetic conditions.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DCFounders
Product
Problem
Systemic and local iron overload disorders, arising from transfusions or genetic conditions, can lead to severe organ damage, neurodegenerative diseases, and vision loss. Current treatments may be limited by tolerability and safety concerns. There is a need for effective, safe, and tolerable therapies to address iron accumulation in both systemic and local contexts.
Solution
Abfero Pharmaceuticals develops oral iron chelators, with a focus on their lead small molecule candidate, SP-420, to treat systemic and local iron overload disorders. SP-420 is designed to target and remove excess iron from the body, including the retina and brain, potentially mitigating damage associated with iron accumulation. The company's technology aims to provide a more tolerable and safer treatment option for patients at risk due to transfusions, genetic conditions, or age-related macular degeneration. By selectively binding to iron, SP-420 aims to reduce iron-related toxicity and improve patient outcomes.
Target Audience
The primary target audience includes patients with systemic iron overload due to transfusions or genetic conditions, as well as individuals with local iron overload contributing to retinal and neurological diseases like age-related macular degeneration.
Features
- Oral small molecule iron chelator for systemic and local iron overload
- SP-420: Brain-penetrant molecule designed to address iron accumulation in the brain and retina
- Targets iron overload resulting from transfusions, genetic conditions, and age-related macular degeneration (AMD)
- Aims to provide a more tolerable and safer treatment option compared to existing therapies
- Clinical-stage pipeline focused on addressing unmet needs in iron overload disorders